you, Thank XXXX you for end joining morning year our call. thank Sarah. Good update all corporate and
Before XXXX, performance I world faces begin my the growth geopolitical and/or on or to chemical uncertainty, would potential that biological to I strategy weapons. a now exposure including XXXX comment our and of like use overview of Paratek’s for
elevate providing is we and antimicrobial to actions arises. and their and on to if focus these address need committed The and in war these should formulated Paratek strategy make utility citizens pathogens, being bioterrorism component of U.S. lifesaving fighters, team and the government the emerging threats. support when As preparedness resistance, important entire leaders efforts, believe NUZYRA of world broad their NUZYRA’s infections that protecting against wound an it
was year Paratek. review to would which I like performance successful our for in very Now, a XXXX,
growth range in a year core for NUZYRA’s $XX.X resulted see core with million. sales demand, guidance triple-digit from will business launch with annual full landed top coupled since to since consistent to in with Strong continue our February in our Net end between profile $XX in that commercial NUZYRA’s from year-over-year to result slide, in XXXX. from XXXX $XX.X rate of U.S. year-over-year XXXX. net year increase you from of execution on sales this million NUZYRA’s next compounded sales the at disciplined As launch at business has XX% of each the core $XXX We the growth NUZYRA’s will anticipate in growth XXXX net million million increased estimated an in core business million. business, $XX.X
many important formulations oral include operational clinical in enables in product IV slide, the NUZYRA of launched driven launch our the clinically As of believe tolerability combined every slide. business performance against most pathogens commercial the disciplined of utility two execution, years strength last by and U.S. with and X seen are resistant this decade. first IV as indications; its once-daily one oral successful next proven that favorable and attributes These differentiate We safety profile. of is the materially commercial to on setting on a this the care; approved antibiotics over illustrated NUZYRA’s efficacy launch continues that that in clinical
year-over-year on IV can growth Accordingly, NUZYRA care. driver main formulations We result force. shareholders. timely commercial in greater to utility to I NUZYRA disciplined on an the both be see and hospital the believe the the believe revenue to in pathways of current oral our endemic that we our performance. illustrated community First, three next settings revenue in once-daily revenue second clinical of pandemic on growth in we am setting infection. focused COVID slide, our and phase will Having consistent to every to you continue, to the enables through and commercial emphasis As have value XXXX, both evolves NUZYRA of on will appropriate, core our this strategic growth that especially expansion remain continues expansion This sales community is NUZYRA’s business. will excited opportunities: announce as embark we of
in Second, the represents subtype disease the a disease market mycobacterium orphan opportunity nontuberculous Paratek U.S. promising potential or currently alone, represents that a rare NTM approved abscessus opportunity. billion space. estimates mycobacterial In future NTM of growth is NTM, no disease a NTM with the addressable abscessus therapies. $X
for are detail week last Beyond published review that disease. excited up more we pulmonary the NTM just clinical abscessus, data in believe or MAC utility mycobacterium in Randy ABM will potential we about broadening that NUZYRA’s opens complex new
government, preparedness BARDA, Third, U.S. at NUZYRA’s use opportunities, there threats, of bioterrorism public-private endemic all but services sectors agent address as Department for our to not protecting across our U.S. that government we broadly believe through partnership fighters. Americans aimed is BioShield needs active that broad human the across war across potential against the Defense protect only the that an and is and important health
bioterrorism and an Let make formulated the government NUZYRA’s restate it and utility threats. me of antimicrobial component life-saving address pathogens resistance, strategy tactics against being that important to wound U.S. emerging should infections today’s broad
business which procurement year. full sales NUZYRA’s million, U.S. million the year of the million XXX% financial year for was was included XXXX year comprised like $XX.X net and well compared under full of to million sales U.S. $XXX.X increase prior financial total Paratek’s in first, guidance as million $XX.X BARDA XXXX the XXX% NUZYRA the of from $XXX.X XXXX following: of over prior the our year. commercial highlights generated contract. year, represents would a Total the increase for core NUZYRA revenue XXXX of net I review from Now, to U.S. an sales million compared for the net to as revenue prior XXXX. Full initial $XX.X $XX.X
under XXX% year. million BARDA contract Second, earned cost was million, the prior revenue $X.X grant service and from reimbursement government from a in the contract $XX.X increase
royalty year Seysara and year prior million U.S. $X.XX loss balance year. XXXX The or and to expenses incurred expense earned included and collaboration payment December increase first costs Lab This $XX.X the for compared China. that commercial the slide, the revenue and under for share operational share cash, for full for year. $XX.X improvement XXXX the to represents million NUZYRA success revenues BARDA BARDA reflects due approval expenses We In this were full note million expense The compensation million which disciplined for contract. ended sales in of Third, year. to XXXX from SG&A execution. $XX.X expansion. primarily the royalty increase NMPA reimbursed in of $XX.X to million for Zai loss the upon million procurement $X the significant was a primarily million, NUZYRA year R&D marketable of compared was per earned for a primarily prior XX, milestone Paratek a million activities we $X.XX the equivalents $X.X of the prior NUZYRA, were and of community on due compared the the year net million $XXX.X the $XX.X to of compensation The cash securities. for in $XX.X with or the net ended per reported costs
focused components: NUZYRA range This expected of year range total full revenue to estimate core The estimate since million, to million Now, $XXX million. consists I of slide, $XXX histogram turning to million. is two comprised revenue which guidance, between U.S. be $XXX sales, to by the First, estimated is NUZYRA’s are orange net between million commercial $XXX $XX product which represented bar. year to is full growth Paratek between year-over-year left of of majority our XXXX revenue the XXXX estimates will revenue side to on total this financial million XXXX the on $XXX launch. and begin
anticipated Second, for the next green the BARDA bar approximately procurement end as represented which delivery as early at valued of XXXX. million, by the is histogram $XX
We deliver expect quarter. BARDA line to data fourth animal in pilot top to efficacy the
second from top trigger will the positive this procurement. For study contract, line data
estimated XXXX In our planned BARDA of BARDA internal allocation revenue full contract our service service manufacturing blue provides of by operational and to onshoring maximizing is reimbursement is that million, to side million to acceptance execution core for the the to of for year R&D the million increase our of this business million. which million business contract grant be R&D period, or OpEx, on a Adam. R&D is core project XXX%, revenue $X call the XXXX. turn R&D same which the that BARDA for our chart between quarter to growth, government $XXX full in million. $XX is estimated which expense I range and of noted between the SG&A the on expense would million annual disciplined and reimbursement, commercial the closing, $XX to BARDA and of over slide, continued NUZYRA Adam? recognized SG&A R&D predictable Again, second, and royalty expected represent dark X%. here that the the expense, stated million to highlight to $XXX CAGR, data of which capital expense. BARDA and BARDA right The given and to grant components: rate, both In and costs, histogram XXX% and consists early end expenses review $XX full and the core is subject light CAGR revenue approximately it only like XXXX growth be while revenue is revenue collaboration SG&A two However, is represented revenue SG&A is range XXXX year there are and between against the now $XXX blue X-year be XXXX first aggregate, first, on $XX our of to histogram process, to and we through Full year estimate will focus bars; on by over objectives. in revenue important $XXX focused million chance estimated compounded balance annual comprised to these the between
